A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

RCT found that treatment with cabozantinib resulted in significantly longer progression free survival vs standard of care with sunitinib (9.0 vs 5.6 months, HR 0.60, 0.37–0.97, p=0.019) as a first line option for advanced papillary renal cell carcinoma.

The Lancet